L-TryptophanPDL |
when sold, a) for human use in oral dosage form at a concentration of more than 220 mg per dosage unit or per daily dose, as a single ingredient or in combination with other ingredients; or b) for human or veterinary use as a single ingredient intended for any route of administration other than oral
|
I |
DEC / 13 |
Labetalol or its saltsPDL |
|
I |
DEC / 13 |
Lacosamide or its derivativesPDL |
|
I |
DEC / 13 |
Lactic acidPDL |
When recommended for parenteral use as a tissue sclerosing agent.
|
I |
DEC / 13 |
Lactulose |
|
III |
SEP / 98 |
Lamivudine or its saltsPDL |
|
I |
DEC / 13 |
Lamotrigine or its saltsPDL |
|
I |
DEC / 13 |
LanadelumabPDL |
|
I |
NOV / 18 |
Lanreotide or its saltsPDL |
|
I |
DEC / 13 |
Lansoprazole or its saltsPDL |
|
I |
DEC / 13 |
Lanthanum saltsPDL |
For human use - when sold for the treatment of hyperphosphatemia.
|
I |
DEC / 13 |
Lapatinib or its saltsPDL |
|
I |
DEC / 13 |
LaronidasePDL |
|
I |
DEC / 13 |
Larotrectinib or its salts PDL |
|
I |
OCT / 19 |
Ledipasvir or its saltsPDL |
|
I |
DEC / 14 |
Lefamulin or its salts PDL |
|
I |
SEP / 20 |
Lefetamine, its salts, derivatives and isomers and salts of derivatives and isomersC |
|
I |
JAN / 03 |
Leflunomide or its salts or derivativesPDL |
Including but not limited to teriflunomide.
|
I |
DEC / 13 |
Lemborexant or its saltsPDL |
|
I |
DEC / 20 |
LenalidomidePDL |
|
I |
DEC / 13 |
Lenvatinib or its saltsPDL |
|
I |
AUG / 16 |
Letermovir or its saltsPDL |
|
I |
DEC / 17 |
LetrozolePDL |
|
I |
DEC / 13 |
Leucovorin or its saltsPDL |
|
I |
DEC / 13 |
Leuprolide or its saltsPDL |
|
I |
DEC / 13 |
Levallorphane and its salts |
|
I |
SEP / 98 |
Levamisole or its saltsPDL |
For human use.
|
I |
DEC / 13 |
Levargorphane and its salts |
|
II |
SEP / 98 |
LevetiracetamPDL |
|
I |
DEC / 13 |
Levobunolol or its saltsPDL |
|
I |
DEC / 13 |
Levocabastine or its salts or derivativesPDL |
|
I |
DEC / 13 |
Levocarnitine or its salts or derivativesPDL |
When sold for the treatment of primary or secondary levocarnitine deficiency.
|
I |
DEC / 13 |
Levodopa or its saltsPDL |
|
I |
DEC / 13 |
Levomilnacipran or its saltsPDL |
|
I |
JUN / 15 |
Levonordefrine |
|
II |
SEP / 98 |
Levonorgestrel |
when sold in concentrations of 1.5 mg or less per oral dosage unit (except when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no more than 1.5 mg levonorgestrel, packaged and labelled for emergency contraception.) |
II |
MAY / 15 |
Levonorgestrel. |
when sold in concentrations of 1.5 mg or less per oral dosage unit to be taken as a single dose of 1.5 mg, packaged and labelled for emergency contraception, in package sizes containing no more than 1.5 mg of levonorgestrel |
III |
MAY / 15 |
LidocainePDL |
For human use - when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher.
|
I |
FEB / 14 |
Lidocaine and its salts |
for ophthalmic or parenteral use, or topical use on mucous membranes, except lozenges |
II |
SEP / 98 |
Lidocaine and its salts. |
for otic use
|
III |
JUN / 06 |
Lidocaine and its salts.. |
for topical use on the skin, including lozenges [except when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher]
|
U |
FEB / 14 |
Lidocaine and prilocaine |
eutectic mixture |
III |
FEB / 99 |
Lifitegrast or its saltsPDL |
|
I |
MAR / 18 |
Linaclotide or its salts or derivativesPDL |
|
I |
DEC / 13 |
Linagliptin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Lincomycin or its salts or derivativesPDL |
Including but not limited to: Clindamycin
|
I |
DEC / 18 |
Lindane |
|
II |
SEP / 98 |
Linezolid or its saltsPDL |
|
I |
DEC / 13 |
Liothyronine or its saltsPDL |
For human use.
|
I |
DEC / 13 |
Lipid solutions in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Liraglutide or its saltsPDL |
|
I |
DEC / 13 |
Lisinopril or its salts or derivativesPDL |
|
I |
DEC / 13 |
Lithium or its saltsPDL |
|
I |
DEC / 13 |
Lixisenatide or its saltsPDL |
|
I |
JUN / 17 |
Lodoxamide or its salts or derivativesPDL |
Including but not limited to Lodoxamide tromethamine.
|
I |
DEC / 13 |
Lomefloxacin or its saltsPDL |
|
I |
DEC / 13 |
Lomitapide or its saltsPDL |
|
I |
FEB / 14 |
LomustinePDL |
|
I |
DEC / 13 |
Loperamide and its salts |
in products marketed for adult use (12 years and older) |
U |
APR / 07 |
Loperamide and its salts. |
in products marketed for paediatric use (under 12 years of age) |
II |
APR / 07 |
LopinavirPDL |
|
I |
DEC / 13 |
Loratadine and its salts and preparations |
in products marketed for paediatric use - under 12 years of age |
III |
OCT / 02 |
Loratadine and its salts and preparations. |
in products marketed for adult use - 12 years and older |
U |
OCT / 02 |
Lorlatinib or its salts PDL |
|
I |
MAR / 19 |
Losartan or its saltsPDL |
|
I |
DEC / 13 |
Losoxantrone or its saltsPDL |
|
I |
DEC / 13 |
LotilanerPDL |
For veterinary use.
|
I |
MAR / 18 |
LovastatinPDL |
Except in oral dosage form that provides 1 milligram (mg) or less per daily dose.
|
I |
DEC / 14 |
Loxapine or its saltsPDL |
|
I |
DEC / 13 |
Lumacaftor or its salts or derivativesPDL |
|
I |
AUG / 16 |
LumiracoxibPDL |
|
I |
DEC / 13 |
Lurasidone or its saltsPDL |
|
I |
DEC / 13 |
LuspaterceptPDL |
|
I |
DEC / 20 |
Lutropin alfaPDL |
|
I |
DEC / 13 |
Lyme Disease vaccine |
|
I |
FEB / 02 |